Lack of Association Between IL-1 Receptor Antagonist Gene 86bp VNTR Polymorphism and Uterine Leiomyoma

Milad Mohammadoo Khorasani 1,2; Saeedeh Salimi 2,3,*; Azam Hajizade 1,2; Maryam Moossavi 4; Ehsan Tabatabai 1,2; Minoo Yaghmaei 5; Lida Namazi 5; Farzaneh Farajian Mashhadi 1,6

1. Background

Uterine leiomyoma (UL), or Uterine fibroid (UF) as a common gynecological tumor, is diagnosed in 22% of women over 35 years of age. The UL symptoms are observed in one-third of patients and make the most common indications for hysterectomy. ULs are benign smooth muscle tumors arising from uterine myometrium smooth-muscle cells containing large amounts of extracellular matrix components such as collagen, fibronectin and proteoglycans. Most patients with these tumors are without symptoms and the tumors grow slowly. ULs can be usually diagnosed by gynecological examination, ultrasonography or hysteroscopy and MRI. Regardless of different investigations, including genetic and molecular studies, the molecular pathology of this compication is still unknown. Leiomyoma is a multisystem disorder and several factors might be involved in its formation, including interactions between multiple genes, hormones, growth factors, cytokines, and environment. Like ovarian and breast cancer, leiomyoma is affected by autocrine and paracrine interactions of sex-steroid hormones. The development of leiomyoma was found to be estrogen dependent and elevated estrogen levels (e.g. in pregnancy) could affect the tumor size.

Several evidences have indicated that immunological and inflammatory processes may play a role in tumor development. Moreover elevated levels of cytokines have been observed in uterine cavity containing leiomyoma compared to normal uterus. The genetic factors contributing to the leiomyoma development have been investigated and the possible effects of cytokine gene polymorphisms in the leiomyoma pathogenesis has been suggested in several studies. Interleukin-1 (IL-1) as a pro-inflammatory cytokine has widespread biological activities and plays an essential role in inflammatory and immune diseases. This cytokine is regulated with interactions of sex-steroid hormones. This study showed that 86bp VNTR polymorphism of IL-1Ra gene is not associated with leiomyoma in the studied population.

Keywords: Leiomyoma; Uterus; Interleukin 1 Receptor Antagonist Protein; Polymorphism, Genetic

1. Background

Uterine leiomyoma (UL), or Uterine fibroid (UF) as a common gynecological tumor, is diagnosed in 22% of women over 35 years of age. The UL symptoms are observed in one-third of patients and make the most common indications for hysterectomy. ULs are benign smooth muscle tumors arising from uterine myometrium smooth-muscle cells containing large amounts of extracellular matrix components such as collagen, fibronectin and proteoglycans. Most patients with these tumors are without symptoms and the tumors grow slowly. ULs can be usually diagnosed by gynecological examination, ultrasonography or hysteroscopy and MRI. Regardless of different investigations, including genetic and molecular studies, the molecular pathology of this complication is still unknown. Leiomyoma is a multisystem disorder and several factors might be involved in its formation, including interactions between multiple genes, hormones, growth factors, cytokines, and environment. Like ovarian and breast cancer, leiomyoma is affected by autocrine and paracrine interactions of sex-steroid hormones. The development of leiomyoma was found to be estrogen dependent and elevated estrogen levels (e.g. in pregnancy) could affect the tumor size.

Several evidences have indicated that immunological and inflammatory processes may play a role in tumor development. Moreover elevated levels of cytokines have been observed in uterine cavity containing leiomyoma compared to normal uterus. The genetic factors contributing to the leiomyoma development have been investigated and the possible effects of cytokine gene polymorphisms in the leiomyoma pathogenesis has been suggested in several studies. Interleukin-1 (IL-1) as a pro-inflammatory cytokine has widespread biological activities and plays an essential role in inflammatory and immune diseases. This cytokine is regulated with interleukin-1 receptor antagonist (IL-1Ra) which binds to IL-1 receptors and blocks the biological activity of IL-1. The IL-1Ra (IL1RN) gene is located on chromosome 2, band q22–q23.

Implication for health policy/practice/research/medical education:

In the present study, the possible association between interleukin-1 receptor antagonist (IL-1Ra) VNTR polymorphism and uterine leiomyoma (UL) has been investigated in an Iranian population in southeast of Iran. We found no association between IL-1Ra VNTR polymorphism and UL risk.

Copyright © 2014, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
There are several polymorphisms in IL-1Ra gene but a variation in repeats of an 86bp variable number of tandem repeat (VNTR) polymorphism in intron 2, is the most studied one. Five alleles have been reported for the IL-1Ra gene VNTR polymorphism: allele 1, four repeats; allele 2, two repeats; allele 3, five repeats; allele 4, three repeats and allele 5, six repeats (15). Moreover IL-1Ra alleles were divided into two groups: long genotypes (L: alleles 1, 3, 4, and 5) and short genotype (S: allele 2). The genotypes were classified as LL, 2L, and 22 (16).

2. Objectives
Since few reports are available about the association between IL-1Ra and leiomyoma a case-control study was conducted to investigate the relationship between IL-1Ra VNTR-polymorphism and leiomyoma in Iranian patients.

3. Patients and Methods
A total number of 99 women with clinically diagnosed UL undergoing surgical intervention at the Department of Obstetrics and Gynecology of the Zahedan University of Medical Sciences were included to the study between 2012 and 2013. UL were diagnosed by detailed sonographic examination and confirmed by histological examination after hysterectomy or myomectomy. 102 age and BMI matched volunteers without leiomyoma recruited for the control group. Non-leiomyoma status was diagnosed after detailed sonographic examination. Blood samples were collected in 2 mL Na-EDTA tubes from patients and healthy controls. The genomic DNA was extracted from peripheral blood leukocytes according to salting out method. Quality and quantity of the extracted DNA were then determined using spectrophotometry (Biophotometer, Eppendrof, Germany). Two oligonucleotide primers forward: 5' - CTC AGC AAC ACT CCT AT -3' and reverse: 5' - TTC CAC CAC ATG GAA C -3' based on flanking region of the IL-1Ra gene were used to amplify the corresponding DNA fragments by polymerase chain reaction (PCR). PCR was performed in a 25 μL final volume containing 25 pmol of each primer, 0.1 mmol of dNTP (Fermentas, Lithuania), 0.5 μg of genomic DNA, 1.5 mmol/L of MgCl₂, 2.5 μL of PCR buffer and 1.5 unit of Taq DNA polymerase (Fermentas, Lithuania) according to the following protocol: initial denaturation at 94°C for 4 min; 30 cycles of denaturation at 94°C for 45 s, annealing at 51°C for 30 s, extension at 72°C for 45 s; and final extension at 72°C for 5 minutes. PCR products were separated by electrophoresis on a 2.5% agarose gel and visualized by ethidium bromide staining (Figure 1).

3.1. Statistical Analysis
Data were analyzed using the statistical software SPSS V. 18 (SPSS, Chicago, IL). Direct gene counting method was used to determine the frequency of alleles. The χ² test or exact test was used to determine IL-1Ra polymorphism. The odds ratio (OR) and 95% confidence intervals (CI) were also estimated. Variations less than 0.05 were considered statistically significant.

4. Results
Demographic data of patients with leiomyoma and control group are shown in Table 1.

![Figure 1] Electrophoretic Pattern of PCR Amplified Products of IL-1 Ra Gene VNTR Polymorphism: M, 50 bp DNA Marker

Table 1. Demographic Data of Patients With Leiomyoma and Control Group

<table>
<thead>
<tr>
<th></th>
<th>Patients (n = 99)</th>
<th>Controls (n = 102)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>38.5 ± 9.8</td>
<td>36.7 ± 5.5</td>
<td>NS</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fars</td>
<td>46 (46)</td>
<td>50 (49)</td>
<td>NS</td>
</tr>
<tr>
<td>Balouch</td>
<td>53 (54)</td>
<td>52 (51)</td>
<td>NS</td>
</tr>
<tr>
<td>Marriage status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>98 (99)</td>
<td>100 (98)</td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.3 ± 4.8</td>
<td>25.4 ± 4.7</td>
<td>NS</td>
</tr>
<tr>
<td>Age of menarche, y</td>
<td>13.1 ± 1.5</td>
<td>13.5 ± 1.1</td>
<td>NS</td>
</tr>
<tr>
<td>Duration of menses, d</td>
<td>6.6 ± 2.7</td>
<td>5.8 ± 1.5</td>
<td>NS</td>
</tr>
<tr>
<td>Menstrual cycle, d</td>
<td>28.6 ± 2.3</td>
<td>29.3 ± 3.4</td>
<td>NS</td>
</tr>
<tr>
<td>Bleeding</td>
<td>57 (58)</td>
<td>6 (6)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Pain</td>
<td>28 (28)</td>
<td>8 (8)</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

a Abbreviations: BMI, body mass building; NS, not significant.
b Data are presented as No. (%) or mean ± SD otherwise it is indicated in the table.
There were no significant differences in age, BMI and marriage status between two groups. No significant differences in menstrual histories, like age of menarche, duration of menses and menstrual cycle were found among the control and disease groups. However the frequency and intensity of bleeding and pain were significantly higher in patients (P < 0.0001). Genotypes and alleles frequency of IL1Ra VNTR polymorphism are shown in Table 2. Six genotypes (1/1, 1/2, 1/3, 2/2, 2/3 and 3/3) of IL1Ra VNTR polymorphism were observed in UL group, however five genotypes of them were also found in control subjects (except 3/3 genotype). Although the frequency of 2/2 genotype was higher in control group, which was not statistically significant (P = 0.08). The frequency of alleles 1 (four repeats), 2 (two repeats) and 3 (five repeats) were 74, 20 and six percent in UL patients and 75, 22 and three percent in healthy controls respectively and not statistically different. Alleles 4 (three repeats) and 5 (six repeats) were not observed in the study population. Moreover no allelic frequency differences were observed between two ethnic groups (P > 0.05)

5. Discussion

According to the findings of the present study, the frequency of the allele 2 of IL-1Ra VNTR polymorphism was lower in patients with leiomyoma than healthy controls (25% vs. 20%); however the difference was not significant. Cytokines are proteins playing key roles in the links between the immunological systems and compromised tissues. A number of cytokines and growth factors, including the ILs family, were investigated in the myometrium and leiomyoma and significantly elevated concentration of serum IL-1 was found in UL patients (17). Inagaki et al. indicated that these cytokines may increase matrix metalloproteinase production, which may result in leiomyoma development stimulation (6). IL-1Ra has anti-inflammatory effects and prevents IL-1 signaling pathway by binding to IL-1 receptors and blocking its biological activity. Some evidences indicated that IL-1Ra may affect the host immune responses in the local and general environments of gynecological cancers (18). Moreover IL-1Ra could decrease tumor growth and angiogenesis (19). Altered IL-1Ra expression levels have been found to correlate with several types of tumors, like endometrial cancer (20) and gastric carcinoma (21). Since IL-1Ra belongs to the IL-1 family (IL-1α, IL-1β, and IL-1Ra) which consist of three linked genes, IL-1 family polymorphisms are located very close to each other. Therefore even mutation in only one of the three genes could alter their expression. Also, different IL-1Ra variants play major roles in IL-1 modulating (22).

There is a 86bp VNTR polymorphism in intron2 of IL-Ra gene, which contains three potential protein binding sites: an interferon α silencer A, an interferon β silencer B and an acute phase response element. It has been reported that the control of cell proliferation activity, was affected by IL-1Ra production through these three binding sites (23). Among the five alleles of IL-1Ra VNTR polymorphism, allele 2 seems to play an important role in the molecular basis of different diseases and autoimmune conditions. Furthermore, increased circulating IL-1Ra and even more elevated IL1β have been observed in individuals with IL-1Ra allele 2 (24). Recently an association between IL-1 family polymorphisms and leiomyoma has been investigated. There is only one published report about the association between IL-1Ra VNTR polymorphism and UL by Hsieh et al. in 2007. In consistent to the present study, they observed no association between IL-1Ra VNTR polymorphism and UL by Hsieh et al. in 2007. In consistent to the present study, they observed no association between IL-1Ra VNTR polymorphism and UL in Taiwan, however they reported a relation between G allele of IL-12Rbeta1 codon 378 and leiomyoma susceptibility (17). Pietrowski et al.

Table 2. Genotypes and Alleles Frequency of IL-1Ra Gene VNTR Polymorphism in Leiomyoma Patients and Control Group a

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Patients (n = 99)</th>
<th>Controls (n = 102)</th>
<th>P Value</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/1</td>
<td>58 (58.6)</td>
<td>61 (60.4)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1/2</td>
<td>24 (24.2)</td>
<td>18 (17.8)</td>
<td>0.23</td>
<td>1.4 (0.7 - 2.9)</td>
</tr>
<tr>
<td>1/3</td>
<td>6 (6.1)</td>
<td>5 (5)</td>
<td>0.5</td>
<td>1.3 (0.4 - 4.4 )</td>
</tr>
<tr>
<td>2/2</td>
<td>7 (7.1)</td>
<td>16 (15.8)</td>
<td>0.08</td>
<td>0.5 (0.2 - 1.2)</td>
</tr>
<tr>
<td>2/3</td>
<td>2 (2)</td>
<td>1 (1)</td>
<td>0.5</td>
<td>2.1 (0.2 - 23.8)</td>
</tr>
<tr>
<td>3/3</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>0.2</td>
<td>2 (1.7 - 2.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Allele</th>
<th>Patients (n = 99)</th>
<th>Controls (n = 102)</th>
<th>P Value</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>146 (74)</td>
<td>145 (72)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>40 (20)</td>
<td>51 (25)</td>
<td>0.2</td>
<td>0.8 (0.5 - 1.3)</td>
</tr>
<tr>
<td>3</td>
<td>12 (6)</td>
<td>6 (3)</td>
<td>0.13</td>
<td>2 (0.7 - 5.4)</td>
</tr>
</tbody>
</table>

a Data are presented as No. (%).
reported an association between IL-1β-511C allele and leiomyoma in Austria (12). Taghizade-Mortezaee et al. demonstrated a significant relationship between IL-1β-511C > T polymorphism and increased risk of UL in Chaharmahal and Bakhtiari province of Iran (25). Other studies have examined the association between IL-1Ra VNTR polymorphism and endometriosis too. Chen et al. in Korea (26) and Hsieh et al. in Taiwan (27) revealed no relation between IL-1Ra VNTR polymorphism and endometriosis. Nevertheless Wen et al. in china indicated that the allele2 of IL-1Ra gene may be a risk factor for endometriosis in the Chinese women (28). These different results are common in association studies and may be due to different genetic backgrounds of various populations.

There were many limitations to this study, like low sample size, environmental conditions and different ethnic groups (Balouch and Fars) existing in Southeast of Iran. Therefore due to the relatively small number of patients with leiomyoma and the racial differences, further investigations using larger sample sizes are necessary to confirm the present findings. In conclusion, the present study showed no association between IL-1Ra gene polymorphism and UL in Southeast of Iran and consequently this polymorphism is not a valuable marker for the prediction of leiomyoma.

Acknowledgements

The authors would like to thank the participants of this study.

Authors’ Contribution

Milad Mohammadoo Khorasani designed the experiments and wrote the paper, Saeedeh Salimi designed the experiments and analyzed the data, Azam Hajizade and Ehsan Tabatabai designed the experiments and performed the experiments, Maryam Moossavi designed the experiments and collected the samples and Farzaneh Farajian Mashhadi designed the experiments and edited the manuscript.

Financial Disclosure

There were no financial disclosures reported.

Funding/Support

The grant (registered number 2161) was received from the research deputy of Zahedan University of Medical Sciences.

References


